FDA WARNING_LETTER - Better Health Labs, Inc. dba Measured - December 31, 2025

The FDA issued a Warning Letter to Better Health Labs, Inc. dba Measured on February 20, 2026, following a December 2025 review of its website, trymeasured.com. The agency found that the company"s marketing of compounded semaglutide and tirzepatide drug products contained false and misleading claims, rendering them misbranded under the Federal Food, Drug, and Cosmetic Act (FDCA). A primary violation involved the website"s implication that Measured was the compounder of these drugs, which is incorrect. Additionally, the company made claims such as "Measured offers compounded GLP-1 treatments made with the same active ingredients found in Wegovy®, Ozempic®, Zepbound®, and Mounjaro®." These statements falsely suggest that the compounded products are FDA-approved or have undergone evaluation for safety and effectiveness, which they have not. Introducing these misbranded products into interstate commerce violates FDCA section 301(a). Measured is required to take immediate action and provide a written response to the FDA within fifteen working days. This response must detail specific steps taken to correct the violations and prevent their recurrence. Essential actions include identifying the actual entities compounding the products, submitting representative labeling samples, and modifying or removing all false or misleading website claims to ensure full compliance with federal law.